Searle & CO. trimmed its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 9.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,712 shares of the company’s stock after selling 4,200 shares during the period. Johnson & Johnson makes up about 1.6% of Searle & CO.’s holdings, making the stock its 17th biggest position. Searle & CO.’s holdings in Johnson & Johnson were worth $6,274,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Summit Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock worth $1,463,000 after purchasing an additional 61 shares in the last quarter. Powers Advisory Group LLC lifted its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after acquiring an additional 61 shares during the last quarter. Citizens & Northern Corp boosted its stake in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company’s stock worth $275,000 after acquiring an additional 63 shares in the last quarter. Eagle Wealth Strategies LLC raised its position in shares of Johnson & Johnson by 2.8% during the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock worth $372,000 after purchasing an additional 63 shares during the period. Finally, Epic Trust Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 3.6% during the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after purchasing an additional 64 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Johnson & Johnson
In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on JNJ
Johnson & Johnson Stock Up 1.5 %
Johnson & Johnson stock opened at $165.86 on Thursday. The company has a market capitalization of $399.17 billion, a P/E ratio of 10.34, a P/E/G ratio of 2.65 and a beta of 0.52. The firm’s fifty day simple moving average is $163.29 and its 200-day simple moving average is $154.92. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the company earned $2.66 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 30.92%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What is a Dividend King?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Tickers Leading a Meme Stock Revival
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Find Undervalued Stocks
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.